Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours

Journal of Pathology

Volumn 232, Issue 1, 2014, Pages 4-15

  Parker, Brittany C ^a,b   Engels, Manon ^a,c   Annala, Matti ^d   Zhang, Wei ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

cancer; FGFR; gene fusions; genomics; pathology; tumourigenesis

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; AZD 4547; CASPASE; CRIZOTINIB; ENZALUTAMIDE; MDV 3011; MICRORNA; PROHIBITIN; RETINOIC ACID; UNCLASSIFIED DRUG;

ANTIANDROGEN THERAPY; BCR ABL GENE; BLADDER CANCER; BREAST CANCER; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE; FIBROBLAST GROWTH FACTOR RECEPTOR 2 GENE; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; FIBROBLAST GROWTH FACTOR RECEPTOR GENE; FUSION GENE; GENE; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE TRANSLOCATION; GLIOBLASTOMA; LUNG CANCER; MOUTH CANCER; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; REVIEW; SLC45A3 GENE; SOLID TUMOR; STOMACH CANCER; THYROID CANCER; TRANSFORMING ACIDIC COILED COIL CONTAINING PROTEIN 3 GENE;

GENOMICS; GLIOBLASTOMA; HUMANS; MUTATION; NEOPLASMS; ONCOGENE FUSION; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 84890019316     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4297     Document Type: Review

References (69)

1. Boveri T., Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci 2008; 121 (Suppl 1): 1-84.
2. Rowley JD,. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
3. Nowell PC, Hungerford DA,. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960; 25: 85-109.
4. Shtivelman E, Lifshitz B, Gale RP, et al., Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550-554.
5. Larson RA, Kondo K, Vardiman JW, et al., Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76: 827-841.
6. Huang ME, Ye YC, Chen SR, et al., Use of all- trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
7. Castaigne S, Chomienne C, Daniel MT, et al., All- trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-1709.
8. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
9. Camidge DR, Bang YJ, Kwak EL, et al., Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019.
10. Tomlins SA, Laxman B, Dhanasekaran SM, et al., Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-599.
11. Tomlins SA, Rhodes DR, Perner S, et al., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
12. Parker BC, Annala MJ, Cogdell DE, et al., The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013; 123: 855-865.
13. Singh D, Chan JM, Zoppoli P, et al., Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337: 1231-1235.
14. Williams SV, Hurst CD, Knowles MA,. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013; 22: 795-803.
15. Martelli MP, Sozzi G, Hernandez L, et al., EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009; 174: 661-670.
16. Powers CJ, McLeskey SW, Wellstein A,. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-197.
17. Turner N, Grose R,. Fibroblast growth factor signalling: from development to cancer. Nature Rev Cancer 2010; 10: 116-129.
18. Holzmann K, Grunt T, Heinzle C, et al., Alternative splicing of fibroblast growth factor receptor IgIII loops in cancer. J Nucleic Acids 2012; 2012: 950508.
19. Dieci MV, Arnedos M, Andre F, et al., Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3: 264-279.
20. Rand V, Huang J, Stockwell T, et al., Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A 2005; 102: 14344-14349.
21. Giri D, Ropiquet F, Ittmann M,. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999; 5: 1063-1071.
22. Theillet C, Adelaide J, Louason G, et al., FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer 1993; 7: 219-226.
23. Weiss J, Sos ML, Seidel D, et al., Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62 ra 93.
24. Byron SA, Gartside M, Powell MA, et al., FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 2012; 7: e30801.
25. Antoniou AC, Spurdle AB, Sinilnikova OM, et al., Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008; 82: 937-948.
26. Jang JH, Shin KH, Park JG,. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001; 61: 3541-3543.
27. van Rhijn BW, Montironi R, Zwarthoff EC, et al., Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002; 198: 245-251.
28. Chesi M, Nardini E, Brents LA, et al., Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet 1997; 16: 260-264.
29. Taylor JG, 6th, Cheuk AT, Tsang PS, et al. Identification of FGFR4 -activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009; 119: 3395-3407.
30. Majewski IJ, Mittempergher L, Davidson NM, et al., Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 2013; 230: 270-276.
31. Seo JS, Ju YS, Lee WC, et al., The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012; 22: 2109-2119.
32. Wu YM, Su F, Kalyana-Sundaram S, et al., Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013; 3: 636-647.
33. Zhang J, Wu G, Miller CP, et al., Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nature Genet 2013; 45: 602-612.
34. Webster MK, Donoghue DJ,. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997; 13: 178-182.
35. Crick FHC,. The packing of alpha-helices-simple coiled-coils. Acta Crystallogr 1953; 6: 689-697.
36. Liu J, Zheng Q, Deng Y, et al., A seven-helix coiled coil. Proc Natl Acad Sci U S A 2006; 103: 15457-15462.
37. Tripet B, Yu L, Bautista DL, et al., Engineering a de novo -designed coiled-coil heterodimerization domain off the rapid detection, purification and characterization of recombinantly expressed peptides and proteins. Protein Eng 1996; 9: 1029-1042.
38. Browman DT, Hoegg MB, Robbins SM,. The SPFH domain-containing proteins: more than lipid raft markers. Trends Cell Biol 2007; 17: 394-402.
39. Emes RD, Ponting CP,. A new sequence motif linking lissencephaly, Treacher Collins and oral-facial-digital type 1 syndromes, microtubule dynamics and cell migration. Hum Mol Genet 2001; 10: 2813-2820.
40. Kim MH, Cooper DR, Oleksy A, et al., The structure of the N-terminal domain of the product of the lissencephaly gene Lis1 and its functional implications. Structure 2004; 12: 987-998.
41. Gerlitz G, Darhin E, Giorgio G, et al., Novel functional features of the Lis-H domain: role in protein dimerization, half-life and cellular localization. Cell Cycle 2005; 4: 1632-1640.
42. Mateja A, Cierpicki T, Paduch M, et al., The dimerization mechanism of LIS1 and its implication for proteins containing the LisH motif. J Mol Biol 2006; 357: 621-631.
43. Millard TH, Bompard G, Heung MY, et al., Structural basis of filopodia formation induced by the IRSp53/MIM homology domain of human IRSp53. EMBO J 2005; 24: 240-250.
44. Yamagishi A, Masuda M, Ohki T, et al., A novel actin bundling/filopodium- forming domain conserved in insulin receptor tyrosine kinase substrate p53 and missing in metastasis protein. J Biol Chem 2004; 279: 14929-14936.
45. Machesky LM, Johnston SA,. MIM: a multifunctional scaffold protein. J Mol Med (Berl) 2007; 85: 569-576.
46. Millard TH, Dawson J, Machesky LM,. Characterisation of IRTKS, a novel IRSp53/MIM family actin regulator with distinct filament bundling properties. J Cell Sci 2007; 120: 1663-1672.
47. Stapleton D, Balan I, Pawson T, et al., The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization. Nature Struct Biol 1999; 6: 44-49.
48. Ponting CP,. SAM: a novel motif in yeast sterile and Drosophila polyhomeotic proteins. Protein Sci 1995; 4: 1928-1930.
49. Schultz J, Ponting CP, Hofmann K, et al., SAM as a protein interaction domain involved in developmental regulation. Protein Sci 1997; 6: 249-253.
50. Kim CA, Bowie JU,. SAM domains: uniform structure, diversity of function. Trends Biochem Sci 2003; 28: 625-628.
51. Chai J, Shiozaki E, Srinivasula SM, et al., Structural basis of caspase-7 inhibition by XIAP. Cell 2001; 104: 769-780.
52. Pop C, Salvesen GS,. Human caspases: activation, specificity, and regulation. J Biol Chem 2009; 284: 21777-21781.
53. Riedl SJ, Fuentes-Prior P, Renatus M, et al., Structural basis for the activation of human procaspase-7. Proc Natl Acad Sci U S A 2001; 98: 14790-14795.
54. Boatright KM, Renatus M, Scott FL, et al., A unified model for apical caspase activation. Mol Cell 2003; 11: 529-541.
55. Johnson DE, Williams LT,. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1-41.
56. Lin B, Ferguson C, White JT, et al., Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999; 59: 4180-4184.
57. Han B, Mehra R, Dhanasekaran SM, et al., A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008; 68: 7629-7637.
58. Xu J, Kalos M, Stolk JA, et al., Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res 2001; 61: 1563-1568.
59. Esgueva R, Perner S, LaFargue CJ, et al., Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010; 23: 539-546.
60. Annala MJ, Parker BC, Zhang W, et al., Fusion genes and their discovery using high throughput sequencing. Cancer Lett 2013; 340: 192-200.
61. Stephens PJ, Greenman CD, Fu B, et al., Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144: 27-40.
62. De S, Michor F,. DNA secondary structures and epigenetic determinants of cancer genome evolution. Nature Struct Mol Biol 2011; 18: 950-955.
63. Fudenberg G, Getz G, Meyerson M, et al., High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nature Biotechnol 2011; 29: 1109-1113.
64. Zhang Y, McCord RP, Ho YJ, et al., Spatial organization of the mouse genome and its role in recurrent chromosomal translocations. Cell 2012; 148: 908-921.
65. Lin C, Yang L, Tanasa B, et al., Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139: 1069-1083.
66. Hughes SE,. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997; 45: 1005-1019.
67. Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression. 2013 [Internet]. [Accessed October 2013]: Available from: http://clinicaltrials.gov/ct2/show/NCT01732107?term= novartis+refractory+urothelial+carcinoma&rank=1
68. Scher HI, Fizazi K, Saad F, et al., Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
69. Parker BC, Zhang W., Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment. Chin J Cancer 2013; 11: 594-603.